BioMarin Pharmaceutical Inc. ã¯ãé節ã§çåœãè
ããåžå°çŸæ£ãç
ç¶ã®æ£è
ã«å¯Ÿããæ²»çæ³ã®éçºãšåååãè¡ã£ãŠããŸããå瀟ã®ååã«ã¯ãéºäŒæ§çŸæ£ã§ããã ã³å€ç³ç I åãæ²»çããããã® Aldurazymeããããã³ç
ã®äžçš®ã§ããåŸæä¹³å
æ§ç¥çµæ§ã»ãã€ããªããã¹ãã³ç 2 åãæ²»çããããã® Brineuraãããã³éºäŒæ§ä»£è¬çŸæ£ã§ãããã§ãã«ã±ãã³å°¿ç (PKU) ã®æ£è
ã®æ²»çã«äœ¿çšããã 6R-BH4 ã®ç¬èªã®åæçµå£å€ Kuvan ãªã©ããããŸããå瀟ã®ååã«ã¯ãã ã³å€ç³ç VI ã®æ£è
ã®ããã® N-ã¢ã»ãã«ã¬ã©ã¯ããµãã³ 4-ã¹ã«ãã¡ã¿ãŒãŒã®çµã¿æãåã§ãã NaglazymeãPKU ã®æäººæ£è
ã®ããã® PEG åçµã¿æããã§ãã«ã¢ã©ãã³ã¢ã³ã¢ãã¢ãªã¢ãŒãŒé
µçŽ ã§ãã Palynziq ããããŸãããŸãããªãœãœãŒã èç©çã§ããã ã³å€ç³çIVåAã®æ²»çãç®çãšããé
µçŽ è£å
çæ³ã§ããVimizimãéçºããŠããŸããããã«ãéçè¡åç
Aã®æ£è
ã®æ²»çãç®çãšãã第3çžèšåºè©Šéšäžã®ã¢ããé䌎ãŠã€ã«ã¹ãã¯ã¿ãŒã§ããvaloctocogene roxaparvovecãããã®äžåè¡¡ãªäœèº«é·ã®äžçš®ã§ããè»éªšç¡åœ¢æçã®æ²»çãç®çãšãã第3çžèšåºè©Šéšäžã®vosoritideãPKUæ£è
ã®è¡äžãã§ãã«ã¢ã©ãã³æ¿åºŠãæ£åžžåããããã®ç¬¬1/2çžèšåºè©Šéšäžã®AAV5åªä»éºäŒåçæ³ã§ããBMN 307ãéºäŒæ§è¡ç®¡æ§æµ®è
«ã®æ²»çãç®çãšããBMN 331ãæ
¢æ§è
çŸæ£ã®æ²»çãç®çãšããBMN 255ããã¥ã·ã§ã³ãåçãžã¹ãããã£ãŒã®æ²»çãç®çãšããBMN 351ãéçºããŠããŸããå瀟ã¯ãSarepta TherapeuticsãAsubio Pharma Co., Ltd.ãDiNAQOR AG ãšææºããã³ã©ã€ã»ã³ã¹å¥çŽãçµãã§ããŸããå瀟ã¯ãç±³åœããšãŒããããã©ãã³ã¢ã¡ãªã«ãããã³åœéçã«ãå°éè¬å±ãç
é¢ãå€åœæ¿åºæ©é¢ããªãã³ã«è²©å£²æ¥è
ããã³å»è¬ååžå£²æ¥è
ã«ãµãŒãã¹ãæäŸããŠããŸããå瀟㯠Allen Institute ãšææºããŠããŸããBioMarin Pharmaceutical Inc. 㯠1996 幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµã³ã©ãã¡ãšã«ã«æ¬ç€Ÿã眮ããŠããŸãã